Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome
- 1 February 1993
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 38 (2), 245-256
- https://doi.org/10.1007/bf01307541
Abstract
Lansoprazole, a new substituted benzimidazole H+, K+-ATPase inhibitor, profoundly inhibits gastric acid secretion and has potential use in the management of diseases such as Zollinger-Ellison syndrome (ZES). In the present study we evaluated the efficacy and safety of lansoprazole in controlling acid hypersecretion in 20 patients with ZES. The starting dose was 60 mg once daily. Control of acid hypersecretion was defined as the dose required to reduce acid secretion to <10 meq/hr in the last hour before the next dose. Doses were adjusted upwards until effective control was achieved. Patients not controlled with 120 mg once daily were placed on twice daily lansoprazole. Most patients (90%) required lansoprazole once daily. During long-term follow-up (mean 18.5 months), 25% of patients required upward dose adjustments and 25% of patients required twice daily lansoprazole. Following cessation of therapy, the mean time for gastric acid output to reach half basal acid output was 39.1 hr. Lansoprazole was well-tolerated without side effects. Clinical chemistry and hematological studies were unchanged, and no gastric carcinoids developed. These results demonstrate that lansoprazole is a safe and effective inhibitor of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Because it has a long duration of action, lansoprazole can be used to control gastric acid hypersecretion in most patients with Zollinger-Ellison syndrome using a once daily dosing schedule.Keywords
This publication has 48 references indexed in Scilit:
- Human gastric acid secretion following repeated doses of AG-1749Alimentary Pharmacology & Therapeutics, 2007
- U.S. experience with omeprazole in duodenal ulcerDigestive Diseases and Sciences, 1991
- Use of omeprazole in patients with Zollinger-Ellison syndromeDigestive Diseases and Sciences, 1991
- Synthesis of 2-(((4-fluoroalkoxy-2-pyridyl)methyl)sulfinyl)-1H-benzimidazoles as antiulcer agents.CHEMICAL & PHARMACEUTICAL BULLETIN, 1990
- Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonistsDigestive Diseases and Sciences, 1986
- OmeprazoleDrugs, 1986
- Basis for failure of cimetidine in patients with Zollinger-Ellison syndromeDigestive Diseases and Sciences, 1984
- Omeprazole in Zollinger–Ellison SyndromeNew England Journal of Medicine, 1984
- CONTROL OF ACUTE ZOLLINGER-ELLISON SYNDROME WITH INTRAVENOUS OMEPRAZOLEThe Lancet, 1982
- Effect of isopropamide on response to oral cimetidine in patients with Zollinger-Ellison syndromeDigestive Diseases and Sciences, 1982